Intrafollicular levels of matrix metalloproteinases-2 and -9 in patients with polycystic ovaries are not associated with pregnancy rate during IVF cycle.

This study aimed to detect the levels of matrix metalloproteinases (MMP)-2 and -9, using enzyme-linked immunosorbent assays, in the follicular fluid of 35 patients with polycystic ovaries, compare them with the levels found in 35 normally ovulating women enrolled in their first in vitro fertilization (IVF) cycle and then correlate them with pregnancy rates in these two groups. Levels of MMP-9 were found significantly increased in women with polycystic ovaries when compared with the controls, while MMP-2 levels were higher in women with polycystic ovaries without reaching statistical significance. The two groups did not differ in age, in the number of embryos transferred or in pregnancy rates. In conclusion, the results indicated an increased gelatinolytic activity in patients with polycystic ovaries after ovarian stimulation for IVF treatment without detecting any association between levels of MMP-2 and 9 and IVF pregnancy rates.

[1]  B. Liu,et al.  Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1 , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[2]  S. Nakajima,et al.  Comparisons of matrix metalloproteinase 1, 2, and 9 activity in periovulatory follicular fluid from natural and stimulated menstrual cycles. , 2006, Fertility and sterility.

[3]  H. Randeva,et al.  Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[4]  Mitsuaki Suzuki,et al.  Serum Matrix Metalloproteinase and Tissue Inhibitor of Metalloproteinase Concentrations in Infertile Women Achieved Pregnancy Following IVF‐ET , 2005, American journal of reproductive immunology.

[5]  Cheorl-Ho Kim,et al.  The expression of matrix metalloproteinase‐9 in human follicular fluid is associated with in vitro fertilisation pregnancy , 2005, BJOG : an international journal of obstetrics and gynaecology.

[6]  S. Goldman,et al.  MMPS and TIMPS in ovarian physiology and pathophysiology. , 2004, Frontiers in bioscience : a journal and virtual library.

[7]  S. D'Ascenzo,et al.  Intrafollicular expression of matrix metalloproteinases and their inhibitors in normally ovulating women compared with patients undergoing in vitro fertilization treatment. , 2004, European journal of endocrinology.

[8]  Stephen B Mooney,et al.  Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human preimplantation embryos. , 2003, Fertility and sterility.

[9]  S. Goldman,et al.  Regulation of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of MMP, and progesterone secretion in luteinized granulosa cells from normally ovulating women with polycystic ovary disease. , 2003, Fertility and sterility.

[10]  S. Al-Hasani,et al.  Matrix metalloproteinases 2 and 9 in follicular fluids of patients undergoing controlled ovarian stimulation for ICSI/ET. , 2003, In vivo.

[11]  Z. Kraiem,et al.  Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization. , 2003, Fertility and sterility.

[12]  T. Sato,et al.  Matrix metalloproteinases-2 and -9 activities in bovine follicular fluid of different-sized follicles: relationship to intra-follicular inhibin and steroid concentrations. , 2003, Domestic animal endocrinology.

[13]  A. H. Gibson,et al.  Secretion of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases into follicular fluid during follicle development in equine ovaries. , 2001, Reproduction.

[14]  S. Goldman,et al.  The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. , 2001, Molecular human reproduction.

[15]  H. Mason,et al.  Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. , 1998, The Journal of clinical endocrinology and metabolism.

[16]  P. Bagavandoss.  Differential distribution of gelatinases and tissue inhibitor of metalloproteinase-1 in the rat ovary. , 1998, The Journal of endocrinology.

[17]  E. Thomas,et al.  Suppression of matrix metalloproteinase production by hCG in cultures of human luteinized granulosa cells as a model for gonadotrophin-induced luteal rescue. , 1996, Journal of Reproduction and Fertility.

[18]  Deanna L Russell,et al.  Immunization against the N-terminal peptide of the inhibin alpha 43-subunit (alpha N) disrupts tissue remodeling and the increase in matrix metalloproteinase-2 during ovulation. , 1995, Endocrinology.

[19]  H. Mason,et al.  Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. , 1994, The Journal of clinical endocrinology and metabolism.

[20]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[21]  L. Matrisian,et al.  Matrix Metalloproteinases as Mediators of Reproductive Function , 2022 .